|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:cyclophosphamide
|
|
gptkbp:activities
|
alkylates DNA
|
|
gptkbp:approves
|
gptkb:FDA
gptkb:EMA
1970s
|
|
gptkbp:brand
|
Busulfex
Myleran
|
|
gptkbp:class
|
gptkb:weapon
sulfonate ester
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
|
|
gptkbp:composed_of
|
alkylation of nitrogen atoms
reacting 1,4-butanediol with sulfur dioxide
|
|
gptkbp:contraindication
|
severe liver disease
hypersensitivity to busulfan
|
|
gptkbp:discovered_by
|
1960s
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:software_framework
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
busulfan
|
|
gptkbp:indication
|
myeloablative therapy
pediatric hematologic malignancies
|
|
gptkbp:ingredients
|
C6 H14 N2 O4 S
|
|
gptkbp:interacts_with
|
gptkb:itraconazole
gptkb:ketoconazole
gptkb:phenytoin
gptkb:warfarin
|
|
gptkbp:is_used_for
|
treatment of chronic myeloid leukemia
conditioning before stem cell transplant
|
|
gptkbp:lifespan
|
approximately 2-3 hours
|
|
gptkbp:manager
|
oral
intravenous
|
|
gptkbp:marketed_as
|
gptkb:Bristol-Myers_Squibb
gptkb:Otsuka_Pharmaceutical
|
|
gptkbp:mass
|
174.25 g/mol
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:side_effect
|
gptkb:fandom
nausea
vomiting
seizures
infertility
skin rash
hepatotoxicity
bone marrow suppression
pulmonary toxicity
secondary malignancies
|
|
gptkbp:social_structure
|
sulfonate
|
|
gptkbp:storage
|
room temperature
protected from light
|
|
gptkbp:type_of
|
55-98-1
|